AVBP Key Statistics, Chart & Performance
The current stock price of AVBP is 20.86 USD. In the past month the price decreased by -6.21%. In the past year, price decreased by -14.54%.
AVBP Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to AVBP. When comparing the yearly performance of all stocks, AVBP is a bad performer in the overall market: 73.05% of all stocks are doing better.
AVBP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AVBP. AVBP has a great financial health rating, but its profitability evaluates not so good.
AVBP Financial Highlights
Over the last trailing twelve months AVBP reported a non-GAAP Earnings per Share(EPS) of -4.24. The EPS decreased by -61.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.36% | ||
| ROE | -49.64% | ||
| Debt/Equity | 0 |
AVBP Forecast & Estimates
19 analysts have analysed AVBP and the average price target is 41.57 USD. This implies a price increase of 99.26% is expected in the next year compared to the current price of 20.86.
AVBP Ownership
AVBP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About AVBP
Company Profile
Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company is headquartered in Newtown Square, Pennsylvania and currently employs 52 full-time employees. The company went IPO on 2024-01-26. The firm is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. The company is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.
Company Info
ARRIVENT BIOPHARMA INC
18 Campus Blvd., Suite 100
Newtown Square PENNSYLVANIA US
Employees: 52
Phone: 12407806356
ARRIVENT BIOPHARMA INC / AVBP FAQ
Can you describe the business of ARRIVENT BIOPHARMA INC?
Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company is headquartered in Newtown Square, Pennsylvania and currently employs 52 full-time employees. The company went IPO on 2024-01-26. The firm is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. The company is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.
What is the stock price of ARRIVENT BIOPHARMA INC today?
The current stock price of AVBP is 20.86 USD. The price decreased by -4.75% in the last trading session.
Does ARRIVENT BIOPHARMA INC pay dividends?
AVBP does not pay a dividend.
What is the ChartMill technical and fundamental rating of AVBP stock?
AVBP has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for AVBP stock?
ARRIVENT BIOPHARMA INC (AVBP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.24).
Can you provide the ownership details for AVBP stock?
You can find the ownership structure of ARRIVENT BIOPHARMA INC (AVBP) on the Ownership tab.
Can you provide the short interest for AVBP stock?
The outstanding short interest for ARRIVENT BIOPHARMA INC (AVBP) is 18.26% of its float.